| Literature DB >> 20676053 |
Alexander Zider1, Donald L Drakeman2.
Abstract
With the rapid growth of monoclonal antibody-based products, new technologies have emerged for creating modified forms of antibodies, including fragments, conjugates and multi-specific antibodies. We created a database of 450 therapeutic antibodies in development to determine which technologies and indications will constitute the "next generation" of antibody products. We conclude that the antibodies of the future will closely resemble the antibodies that have already been approved for commercial sale.Mesh:
Substances:
Year: 2010 PMID: 20676053 PMCID: PMC3180083 DOI: 10.4161/mabs.12461
Source DB: PubMed Journal: MAbs ISSN: 1942-0862 Impact factor: 5.857